The inhibition of the ATM/CHK2/P53 pathway alone may be not sufficient to eliminate tumor cells, so drugs targeting the ATR/CHK1/WEE1 pathway have been simultaneously developed to serve as an effective treatment for immune-checkpoint-inhibitor-resistant endometrial cancer. This evidence concerns the gene CHEK2 and endometrial cancer.